Stocks and Investing
Stocks and Investing
Wed, March 2, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, March 1, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Lebowitz Initiated (ASND) at Strong Buy and Held Target at $187 on, Mar 1st, 2022
David Lebowitz of Citigroup, Initiated "Ascendis Pharma A/S" (ASND) at Strong Buy and Held Target at $187 on, Mar 1st, 2022.
David has made no other calls on ASND in the last 4 months.
There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022
These are the ratings of the 4 analyists that currently disagree with David
- Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
- Derek Archila of "Wells Fargo" Initiated at Buy and Held Target at $176 on, Wednesday, December 8th, 2021
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $179 on, Thursday, November 11th, 2021
Contributing Sources